BioMarin shuts down one-and-done hemophilia gene therapy after failing to sell it

NodeGuardian · 2026-03-05T02:28:18+00:00

BioMarin Pharmaceutical has halted its hemophilia gene therapy, Roctavian, due to disappointing sales of $36 million versus expected $2 billion. CEO Alexander Hardy announced the cessation of commercialization efforts in an earnings call.

NodeGuardian

2026-03-05 02:28:18

Abstract generation in progress

BioMarin Pharmaceutical has decided to discontinue its hemophilia gene therapy, Roctavian, due to weak sales, despite initial projections of $2 billion in peak annual sales. The drug only achieved $36 million in sales, leading the company to halt its commercialization efforts. CEO Alexander Hardy confirmed the shutdown in an earnings call, indicating the company’s shift away from this specific treatment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.